18F-FBY PET/CT在健康志愿者与胶质瘤患者中的首次人体研究
该首次人体研究评估了靶向LAT-1的PET示踪剂18F-FBY的安全性、生物分布与辐射剂量学,并在疑似胶质瘤患者中分析其摄取与LAT-1表达的相关性。6名健康志愿者耐受良好,有效剂量为0.0039 ± 0.0006 mSv/MBq;14例手术确诊胶质瘤中,高级别肿瘤的SUVmax和T/N比值显著高于低级别,且SUVmax与LAT-1表达及Ki-67指数正相关。
要点
- 18F-FBY在健康志愿者中耐受良好,主要经肾脏和泌尿道排泄。
- 14例胶质瘤中,高级别肿瘤SUVmax和T/N比值显著高于低级别(P < 0.001)。
- SUVmax与LAT-1表达(r2 = 0.80)及Ki-67指数(r2 = 0.79)正相关。
核心结论
- 18F-FBY是具有良好剂量学特征和药代动力学的PET示踪剂,有潜力评估胶质瘤LAT-1表达,并可能为胶质瘤硼中子俘获治疗提供影像指导。
研究设计与样本
- 首次人体研究,纳入6名健康志愿者(3男3女)行多时间点全身PET采集,计算器官TACs并用OLINDA/EXM软件估算剂量学。
主要发现
- 18F-FBY在所有健康志愿者中耐受良好,未观察到或报告不良反应。
- 18F-FBY快速从血液循环清除,主要经肾脏和泌尿道排泄,有效剂量为0.0039 ± 0.0006 mSv/MBq。
- 14例手术确诊胶质瘤中(1例患者有2个胶质瘤),低级别肿瘤SUVmax为0.28 ± 0.14、T/N比值为2.30 ± 1.26;高级别肿瘤SUVmax为2.84 ± 0.46、T/N比值为24.56 ± 6.32。
- 低级别与高级别胶质瘤摄取差异显著(P < 0.001),免疫组化证实SUVmax与LAT-1表达(r2 = 0.80,P < 0.001)及Ki-67标记指数(r2 = 0.79,P < 0.001)正相关。
关键数值与推荐
- 健康志愿者有效剂量(ED)为0.0039 ± 0.0006 mSv/MBq。
- 低级别胶质瘤SUVmax 0.28 ± 0.14、T/N比值2.30 ± 1.26;高级别胶质瘤SUVmax 2.84 ± 0.46、T/N比值24.56 ± 6.32。
- 低级别与高级别胶质瘤摄取差异P < 0.001;SUVmax与LAT-1表达r2 = 0.80(P < 0.001),与Ki-67指数r2 = 0.79(P < 0.001)。
临床怎么用
- 18F-FBY PET/CT可用于无创评估胶质瘤LAT-1表达水平,辅助区分低级别与高级别胶质瘤。
- 该示踪剂可能为胶质瘤硼中子俘获治疗的病例筛选和疗效监测提供影像学依据。
局限性
- 研究为首次人体探索性研究,尚需更大样本验证诊断效能与临床获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In this work, the safety, biodistribution, and radiation dosimetry of large neutral amino acid transporter type-1 (LAT-1) targeting PET tracer 18F-trifluorobborate-derived tyrosine (denoted as 18F-FBY) has been investigated. It is designed as a first-in-human study in healthy volunteers and to assay LAT-1 expression level in glioma patients. METHODS: Six healthy volunteers (3 M, 3 F) underwent whole-body PET acquisitions at multiple time points after bolus injection of 18F-FBY. Regions of interest (ROIs) were mapped manually on major organs, and then the time-activity curves (TACs) were obtained. Dosimetry was calculated with the OLINDA/EXM software. Thirteen patients who were suspected of glioma were scanned with PET/CT at 30 min after 18F-FBY injection. Within 7 days after PET/CT, the tumor was removed surgically, and LAT-1 immunohistochemical staining for LAT-1 was performed on tumor samples and correlated with 18F-FBY PET imaging. RESULTS: 18F-FBY was well tolerated by all healthy volunteers, and no adverse symptoms were observed or reported. 18F-FBY is rapidly cleared from the blood circulation and excreted mainly through the kidneys and urinary tract. The effective dose (ED) was 0.0039 ± 0.0006 mSv/MBq. In 14 surgical confirmed gliomas (one of the patiens had two gliomas), 18F-FBY uptake increased consistently with tumor grade, with maximum standard uptake values (SUVmax) of 0.28 ± 0.14 and 2.84 ± 0.46 and tumor-to-normal contralateral activity (T/N) ratio of 2.30 ± 1.26 and 24.56 ± 6.32 in low- and high-grade tumors, respectively. In addition to the significant difference in the uptakes between low- and high-grade gliomas (P < 0.001), the immunohistochemical staining confirmed the positive correlations between the SUVmax, LAT-1 expression (r2 = 0.80, P < 0.001), and Ki-67 labeling index (r2 = 0.79, P < 0.001). CONCLUSION: 18F-FBY is a PET tracer with favorable dosimetry profile and pharmacokinetics. It has the potential to assay LAT-1 expression in glioma patients and may provide imaging guidance for further boron neutron capture therapy of gliomas. TRIAL REGISTRATION: clinicaltrials.gov (NCT03980431).
引用
- Li Z, Kong Z, Chen J, et al. 18F-Boramino acid PET/CT in healthy volunteers and glioma patients. Eur J Nucl Med Mol Imaging. 2021. PMID: 33590273. doi:10.1007/s00259-021-05212-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。